Lyndra Therapeutics

Based in the US, Lyndra Therapeutics, Inc. is dedicated to transforming oral drug delivery through its innovative LYNX™ platform, improving medication adherence and patient outcomes in chronic health conditions. Lyndra Therapeutics is focused on developing advanced oral drug delivery solutions to enhance the treatment experience. Founded in Watertown, US, in 2015 by Colin Gardner and Giovanni Traverso, the company has completed a total of 7 funding deals.

Its most recent funding was a Series E round in December 2023, raising USD 122. 75 mn led by Sarissa Capital Management, with participation from Sun Pharmaceutical Industries Limited and Polaris Partners. Lyndra Therapeutics is currently valued at USD 210. 209 mn.

Lyndra Therapeutics specializes in innovative oral drug delivery solutions, primarily through its flagship LYNX™ drug delivery platform. This platform is designed to revolutionize patient experiences by minimizing the need for daily pill consumption, addressing medication adherence challenges faced by individuals with various health conditions. The technology enables the development of long-acting oral therapies that provide sustained therapeutic effects, simplifying treatment regimens for patients. The company targets a diverse client base, including healthcare providers, pharmaceutical partners, and patients across multiple regions such as North America and Europe, with a focus on chronic conditions requiring consistent medication.

Lyndra Therapeutics generated revenue of USD 11. 00 mn in 2022. The company derives its income through collaborative partnerships with pharmaceutical companies and healthcare organizations, providing its LYNX™ platform for the development of long-acting oral therapies tailored to specific medical needs. Revenue streams include milestone payments, licensing fees, and revenue sharing based on product performance, enhancing its visibility within the pharmaceutical landscape.

In December 2023, Lyndra Therapeutics raised USD 122. 75 mn in Series E funding, which will be utilized to further develop its trial programs. The company aims to introduce new products designed to enhance patient adherence and expand its reach into international markets, particularly in Europe and Asia, by 2025. This growth strategy will support its commitment to addressing the evolving needs of healthcare providers and patients.